Farydak

Farydak Uses, Dosage, Side Effects, Food Interaction and all others data.

Farydak is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Farydak is marketed by Novartis under the brand name Farydak. Farydak acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.

Farydak
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Farydak
Availability	Discontinued
Generic	Panobinostat
Panobinostat Other Names	Panobinostat, Panobinostatum
Related Drugs	Revlimid, Velcade, Darzalex, Pomalyst, Ninlaro, Kyprolis
Weight	10mg, 15mg, 20mg,
Type	Capsule, Oral Capsule
Formula	C₂₁H₂₃N₃O₂
Weight	Average: 349.434 Monoisotopic: 349.179026993
Groups	Approved, Investigational
Therapeutic Class
Manufacturer	Secura Bio Limited
Available Country	United Kingdom, United States,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Farydak is a non-selective histone deacetylase inhibitor used to treat multiple myeloma in combination with other antineoplastic agents.

Farydak is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.

Farydak is also used to associated treatment for these conditions: Refractory Multiple Myeloma

How Farydak works

Farydak is a deacetylase (DAC) inhibitor. DACs, also known as histone DACs (HDAC), are responsible for regulating the acetylation of about 1750 proteins in the body; their functions are involved in many biological processes including DNA replication and repair, chromatin remodelling, transcription of genes, progression of the cell-cycle, protein degradation and cytoskeletal reorganization. In multiple myeloma, there is an overexpression of DAC proteins. Farydak inhibits class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10) and class IV (HDAC 11) proteins. Farydak's antitumor activity is believed to be attributed to epigenetic modulation of gene expression and inhibition of protein metabolism. Farydak also exhibits cytotoxic synergy with bortezomib, a proteasome inhibitor concurrently used in treatment of multiple myeloma.

Toxicity

Farydak carries a Boxed Warning alerting patients and health care professionals that severe diarrhea and severe and fatal cardiac events, arrhythmias and electrocardiogram (ECG) changes have occurred in patients receiving Farydak. Because of these risks, Farydak is being approved with a Risk Evaluation and Mitigation Strategy (REMS) consisting of a communication plan to inform health care professionals of these risks and how to minimize them.

Food Interaction

Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of panobinostat.
Exercise caution with St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce the serum concentration of panobinostat.
Take at the same time every day.
Take with a full glass of water.
Take with or without food.

[Moderate] GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of panobinostat.

The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.

Increased exposure to panobinostat may increase the risk of adverse effects such as nausea, vomiting, diarrhea, anorexia, peripheral edema, cardiotoxicity, ECG abnormalities, electrolyte disturbances, bleeding complications, hepatotoxicity, and myelosuppression.

Food may delay the rate of absorption of panobinostat, but does not significantly affect the overall extent of absorption.

When a single oral dose of panobinostat was administered to 36 patients with advanced cancer 30 minutes after a high-fat meal, panobinostat peak plasma concentration (Cmax) and systemic exposure (AUC) were approximately 44% and 16% lower, respectively, compared to administration under fasting conditions.

The median time to maximum concentration (Tmax) was prolonged by 2.5 hours.

MANAGEMENT: Patients should avoid consumption of grapefruit or grapefruit juice during treatment with panobinostat.

The manufacturer also recommends avoiding star fruit, Seville oranges, pomegranate, and pomegranate juice.

Farydak may be administered with or without food.